^
Phase 3
Merck Sharp & Dohme LLC
Recruiting
Last update posted :
06/14/2024
Initiation :
04/07/2021
Primary completion :
04/21/2026
Completion :
06/05/2028
EGFR • PD-L1 • ALK • ROS1 • PD-1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)
Phase 1
Merck Sharp & Dohme LLC
Active, not recruiting
Last update posted :
04/18/2024
Initiation :
12/13/2016
Primary completion :
08/01/2024
Completion :
08/01/2024
HER-2
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • etoposide IV • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)
Phase 2
Merck Sharp & Dohme LLC
Active, not recruiting
Last update posted :
04/02/2024
Initiation :
04/20/2021
Primary completion :
01/26/2023
Completion :
08/13/2027
EGFR • ALK
|
Keytruda (pembrolizumab) • docetaxel • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)